WO2010086441A1 - Pharmaceutical composition comprising n-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride - Google Patents

Pharmaceutical composition comprising n-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride Download PDF

Info

Publication number
WO2010086441A1
WO2010086441A1 PCT/EP2010/051174 EP2010051174W WO2010086441A1 WO 2010086441 A1 WO2010086441 A1 WO 2010086441A1 EP 2010051174 W EP2010051174 W EP 2010051174W WO 2010086441 A1 WO2010086441 A1 WO 2010086441A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
polymorph
ethynylphenyl
methoxyethoxy
bis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2010/051174
Other languages
French (fr)
Inventor
Sandra Brueck
Konstantin Holfinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ratiopharm GmbH
Original Assignee
Ratiopharm GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ratiopharm GmbH filed Critical Ratiopharm GmbH
Publication of WO2010086441A1 publication Critical patent/WO2010086441A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • composition comprising N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising N-(3- ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride as active pharmaceutical ingredient and a process for the preparation of such composition.
  • Erlotinib N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine
  • Erlotinib HCI has the following formula (I):
  • this compound is an inhibitor of tyrosine kinase enzymes, namely as epidermal growth factor receptors and can be used for the treatment and/or prevention of diseases which are associated with tyrosine kinase enzymes such as epidermal growth factor receptors, such as cancer, particularly non small cell lung cancer, colorectal cancer, refractory non small cell lung cancer, pancreatic cancer, ovarian cancer, breast cancer, glioma, head cancer or neck cancer.
  • tyrosine kinase enzymes namely as epidermal growth factor receptors
  • diseases which are associated with tyrosine kinase enzymes such as epidermal growth factor receptors, such as cancer, particularly non small cell lung cancer, colorectal cancer, refractory non small cell lung cancer, pancreatic cancer, ovarian cancer, breast cancer, glioma, head cancer or neck cancer.
  • polymorph A and polymorph B Two different polymorphs of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4- quinazolinamine hydrochloride, designated as polymorph A and polymorph B, have been disclosed in WO 01/34574, which is incorporated herein by reference.
  • Polymorph B was found to be thermodynamically more stable than polymorph A. This document therefore also discloses a method comprising the step of recrystallisation of a compound comprising both polymorph A and polymorph B into the more stable polymorph B. The more stable polymorph B is further used in the preparation of pharmaceutical compositions.
  • polymorph E A further polymorph of the compound N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4- quinazolinamine hydrochloride, namely polymorph E is disclosed in WO 2004/072049.
  • polymorph B is thermodynamically more stable than polymorph A
  • polymorph A exhibits a better solubility and dissolution rate than polymorph B.
  • Polymorph E is said to unexpectedly exhibit the desired increased solubility and dissolution rate with respect to polymorph B and an increased thermodynamic stability compared to polymorph A.
  • WO 2006/110811 relates to the problem that conventional Erlotinib HCI tablets are only very slightly soluble in water at 37°C. Therefore, the dissolution of conventional Erlotinib HCI tablets is said to be reduced in the fasted state as compared to the fed state. Thus, Erlotinib HCI has limited bioavailability in the fasted state as compared to the fed state, which limits the therapeutic outcome for all treatments requiring Erlotinib HCI.
  • nanoparticulate Erlotinib HCI composition comprising particles of the active pharmaceutical ingredient having an effective average particle size of less than 2000 nm and at least one surface stabilizer is suggested.
  • the surface stabilizer is present to stabilize the nanoparticulate form of the composition.
  • a wide range of surface stabilizers is disclosed, including various polymers, low molecular weight oligomers, natural products, and surfactants.
  • the surface stabilizers include non-ionic, ionic anionic, cationic, and zwitterionic compounds or surfactants.
  • Sodium lauryl sulfate is exemplified among a large list of further compounds.
  • Nanoparticles are difficult to prepare, costly, and difficult to handle when preparing pharmaceutical dosage forms. Therefore, there is a need for further pharmaceutical compositions comprising Erlotinib HCI which overcome the above problems of the prior art, in particular with respect to preparation and handling characteristics, solubility, bioavailability and stability.
  • the present invention relates to a pharmaceutical composition comprising N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4- quinazolinamine hydrochloride in a thermodynamically stable form.
  • Erlotinib HCI can be synthesized using techniques well-known in the art. A synthesis of Erlotinib is disclosed, for example, in WO 96/30347.
  • Polymorph A of Erlotinib HCI and a method of its preparation is disclosed in WO 01/34574.
  • the X-ray powder diffraction pattern of polymorph A of Erlotinib HCI is shown in attached figure 1.
  • 2-Theta values of characteristic peaks taken from the X-ray powder diffraction pattern of polymorph A of Erlotinib HCI and their relative intensities are summarized in the following table 1.
  • polymorph A of Erlotinib HCI is characterized by having characteristic peaks in an X- ray powder diffraction pattern when measured with Cuk ⁇ radiation expressed in degrees 2- theta at approximately 5.6, 9.8, 18.9 and 23.5.
  • pharmaceutical composition refers to single dosage forms, such as tablets, capsules, pellets, etc., as well as powders or granules which are used in the preparation of single dosage forms. Where it is referred to the total weight of the pharmaceutical composition and the pharmaceutical composition is in a single dosage form, the total weight is the weight of the single dosage form excluding, if applicable, the weight of any coating or capsule shell.
  • polymorph A of Erlotinib HCI is thermodynamically unstable.
  • attached figure 2 which shows the X-ray powder diffraction (XRPD) pattern of a mixture of 90 parts by weight polymorph A and 10 parts by weights polymorph B during storage for 0, 4 and 12 weeks respectively (from bottom to top). From the diffraction patterns it can be seen that the characteristic peaks of polymorph A are decreasing while the characteristic peaks of polymorph B are increasing over time.
  • XRPD X-ray powder diffraction
  • the relative intensities of the polymorph A peak at a 2-theta angle of 5.6 are decreasing from the bottom to the top while the relative intensities of the polymorph B peak at a 2-theta angle of 6.3 are significantly increasing from the bottom to the top, i.e. during storing for 0, 4 and 12 weeks, respectively.
  • the present invention is based on the surprising finding that polymorph A of Erlotinib HCI can be incorporated into a pharmaceutical composition in a thermodynamically stable form.
  • "Thermodynamically stable" in the sense of the present invention means that in the pharmaceutical composition Erlotinib HCI maintains its polymorphic form A even under harsh storage conditions of 75 % relative humidity and 4O 0 C for at least 12 weeks, preferably for at least 12 months. Maintaining its polymorphic form A therefore means that polymorph A of Erlotinib HCI during storage is not converted into any other polymorph of Erlotinib HCI, in particular not into polymorph B.
  • thermodynamic stability of polymorph A of Erlotinib HCI in the pharmaceutical compositon of the present invention is confirmed by attached figure 3 which shows the XRPD patterns of grounded tablets of the present invention at time 0, after 4 weeks and after 12 weeks storage at 75 % relative humidity and 4O 0 C (from bottom to top). It is evident that the characteristic peaks of polymorph A of Erlotinib HCI do not change in their intensities. Moreover, none of the characteristic peaks of polymorph B of Erlotinib HCI (shown as lines and dots at the bottom of the diagram) occurs in the XRPD patterns of the tablet. This confirms that polymorph A of Erlotinib HCI is thermodynamically stable in the pharmaceutical composition of the present invention and in particular that polymorph A is not converted into polymorph B during storage over at least 12 weeks.
  • polymorph A of Erlotinib HCI can be thermodynamically stabilized by the addition of a hydrophilic excipient to the pharmaceutical composition. Further surprising it was found that the addition of a hydrophilic excipient does not only stabilize the polymorphic form of the active pharmaceutical ingredient, but the hydrophilic excipient additionally increases the dissolution of the pharmaceutical composition. Moreover, the increased dissolution is obtained without the requirement of providing the Erlotinib HCI in nanoparticulate form. Thus, the combination of polymorph A of Erlotinib HCI and a hydrophilic excipient in the pharmaceutical composition of the present invention results in several advantages over the prior art formulations.
  • the first advantage is that polymorph A of Erlotinib HCI, which is known to be thermodynamically unstable, is stabilized, a further advantage is that the dissolution of the pharmaceutical composition and thereby the bioavailability of the active pharmaceutical ingredient is increased, and a further advantage is that dissolution and/or bioavailability are increased without the requirement of providing the active pharmaceutical ingredient in nanoparticulate form.
  • Hydrophilic excipients in the sense of the present invention contain molecules that are charge-polarized and capable of hydrogen bonding, enabling them to dissolve more readily in water than in oil or other hydrophobic solvents.
  • a hydrophilic excipient can, for example, be a hydrophilic polymer which contains hydrophilic groups, such as hydroxy groups, amino groups, carboxy groups and/or sulfonate groups.
  • hydrophilic polymers are polysaccharides, such as microcrystalline cellulose (MCC), hydroxypropylmethyl cellulose (HPMC), carboxymethyl celluloses (CMC) (in particular sodium carboxymethyl cellulose or calcium carboxymethyl cellulose), ethyl cellulose, methyl cellulose, hydroxyethyl cellulose, ethylhydroxyethyl cellulose, and hydroxypropyl cellulose (HPC); polyvinyl pyrrolidone; polyvinyl alcohol; acrylic acid polymers and there salts; polyacryl amides; polymethacrylates; copolymers of vinylpyrrolidone and vinylacetate (such as Kollidon ® VA64); polyalkylene glycols, such as polypropylene glycol and polyethylene glycol; block copolymers of polyethylene glycols, such as block copolymers of polyethylene glycol and polypropylene glycol (such as Pluronic ® ).
  • the hydrophilic polymer can have a weight average molecular weight in
  • Microcrystalline cellulose is a preferred hydrophilic excipient in the pharmaceutical composition of the present invention.
  • the microcrystalline cellulose can have a specific surface area in the range of about 0.78 m 2 /g to about 1.30 m 2 /g and/or a mean particle size in the range of about 10 ⁇ m to about 100 ⁇ m.
  • hydrophilic excipients useful in the pharmaceutical composition of the present invention are, for example, monosaccharides, disaccharides, oligosaccharides and sugar alcohols, such as mannitol, sorbitol, xylitol, isomalt, glucose, fructose or maltose.
  • the pharmaceutical composition of the present invention can contain one or more hydrophilic excipients.
  • the hydrophilic excipient is not a surfactant, i.e. it does not contain hydrophilic and hydrophobic parts, such as the hydrophobic fatty acid residue in sodium lauryl sulfate.
  • the hydrophilic excipient is a hydrophilic polymer, a 2 wt.% solution of which in water exhibits a viscosity in the range of about 0.01 mPa/s to about 8 mPa/s, preferably in the range of about 0.5 mPa/s to about 7 mPa/s, more preferably in the range of about 1 mPa/s to about 6 mPa/s.
  • the amount of hydrophilic excipient present in the pharmaceutical composition of the present invention is not particularly limited. It can be selected by the person skilled in the art based on the specific requirements of the composition, for example with respect to its compressability. The amount must, however, be sufficient to thermodynamically stabilize polymorphic form A of Erlotinib HCI.
  • the amount can be in the range of about 10 wt.% to about 90 wt.%, preferably in the range of about 10 wt.% to about 75 wt.%, more preferably in the range of about 30 wt.% to about 75 wt.%, most preferred in the range of about 50 wt.% to about 70 wt.%, each based on the total weight of the pharmaceutical composition.
  • the pharmaceutical composition is essentially free of polymorph B of Erlotinib HCI.
  • Being essentially free of polymorph B means that polymorph B is present in the pharmaceutical composition of the present invention in an amount of less than 5 wt.%, preferably in an amount of less than 1 wt.%, each based on the total amount of Erlotinib HCI.
  • the pharmaceutical composition of the present invention does not contain any polymorph B of Erlotinib HCI.
  • the pharmaceutical composition does not contain any other polymorph of Erlotinib HCI than polymorph A.
  • the pharmaceutical composition of the present invention preferably comprises Erlotinib HCI essentially only as polymorph A, i.e. at least 95 wt.% of the total amount of Erlotinib HCI in the pharmaceutical composition is present in polymorphic form A, preferably at least 99 wt.%. Most preferred Erlotinib HCI is present in the pharmaceutical composition only in polymorphic form A.
  • the particle size of the active pharmaceutical ingredient in the pharmaceutical composition of the present invention is not particularly limited. However, in view of the disadvantages associated with the preparation and handling of nanoparticles, it is preferred that the Erlotinib HCI in the pharmaceutical composition of the present invention has a D50 particle size of above 2 ⁇ m. D50 particle size means a particle size distribution where 50 vol.% of the total amount of Erlotinib HCI in the pharmaceutical composition has a particle size of above 2 ⁇ m when measured with a Master Sizer 2000 using propan-2-ol as dispersant.
  • thermodynamic stability of polymorph A of Erlotinib HCI and the dissolution of the pharmaceutical composition are particularly strong when the surface stabilizer is absorbed to or associated with the surface of the Erlotinib HCI particles.
  • This absorption or association can be obtained by intimate mixing polymorph A of Erlotinib HCI and the hydrophilic excipient, for example, by milling, grinding, or triturating.
  • the present invention also relates to a process for the preparation of a pharmaceutical composition as defined above, comprising the step of intimate mixing polymorph A of Erlotinib HCI and a hydrophilic excipient.
  • the step of intimate mixing is carried out by milling, grinding, or triturating.
  • the process can comprise the further steps of adding additional excipients and forming a solid dosage form, such as by compression, in particular by dry compaction.
  • the pharmaceutical composition of the present invention can additionally comprise one or more further active pharmaceutical ingredients, in particular one or more compounds useful in treating hyperproliferative disorders, such as cancer or other neoplastic diseases, or the pharmaceutical composition of the present invention can be administered in conjunction with such a compound.
  • suitable other active pharmaceutical ingredients are disclosed, for example, in WO 2006/110811.
  • the dosage of Erlotinib HCI can vary within wide limits depending on the disease to be controlled, the age and the individual condition of the patient and the mode of administration, and will, of course, be fit to the individual requirements in each particular case. For adult patients a daily dosage of about 1 mg to about 1000 mg, especially about 5 mg to about 500 mg, preferably about 25 mg to about 200 mg is applicable. Depending on severity of the disease and the precise pharmacokinetic profile, the compound can be administered with one or several daily dosage units, e.g. in one to three dosage units.
  • the pharmaceutical composition of the present invention may further comprise one or more pharmaceutically acceptable excipients, such as fillers, binding agents, lubricants, flow enhancers, antisticking agents, disintegrating agents and solubilizers.
  • the fillers are lactose, mannitol, sorbitol or microcrystalline cellulose.
  • the filler is suitably present in an amount of about 0 wt.% to about 30 wt.% of the total weight of the composition.
  • the binding agent can for example be microcrystalline cellulose (MCC) or hydroxypropylmethyl cellulose (HPMC).
  • MCC microcrystalline cellulose
  • HPMC hydroxypropylmethyl cellulose
  • the binding agent is present in an amount of about 1 wt.% to about 25 wt.%, more preferably at about 2 wt.% to about 10 wt.% of the total weight of the composition.
  • the lubricant is preferably a stearate such as earth alkali metal stearate, such as magnesium stearate or sodium stearyl fumarate.
  • the lubricant is suitably present in an amount of about 0.5 wt.% to about 2.5 wt.% of the total weight of the composition.
  • Suitable disintegrating agents are for example cellulose derivatives such croscarmellose sodium, starch derivatives such as sodium carboxymethyl starch, pregelatinized starch, synthetic polymers such as cross-linked polyvinylpyrrolidone (crospovidone) or sodium bicarbonate.
  • the disintegrant or disintegrant mixture is suitably present in an amount of about 1 wt.% to about 20 wt.%, more preferably at about 5 wt.% to about 10 wt.% of the total weight of the composition.
  • the flow enhancer can for example be colloidal silicon dioxide.
  • the flow enhancer is present in an amount of about 0.5 wt.% to about 8 wt.%, more preferably at about 1 wt.% to about 4 wt.% of the total weight of the composition.
  • the antisticking agent is for example talcum and may be present in amounts of about 1 wt.% to about 5 wt.%, more preferably in an amount of about 1.5 wt.% to about 3 wt.% of the total weight of the composition.
  • An improvement of the solubility of the active pharmaceutical ingredient can for example be achieved by the addition of complex forming agents/compounds (e.g. sodium benzoate, sodium salicylate or cyclodextrins), the alternation of solvent properties (e.g. by adding PVP or polyethylene glycols) or the addition of solubilizers which form tenside micelles (e.g. surfactants).
  • complex forming agents/compounds e.g. sodium benzoate, sodium salicylate or cyclodextrins
  • solvent properties e.g. by adding PVP or polyethylene glycols
  • solubilizers which form tenside micelles e.g. surfactants.
  • Suitable solubilizers are for example surfactants such as polyoxyethylene alcohol ethers (e.g. Brij®), polysorbates (e.g. Tween®) or polyoxypropylene polyoxyethylene copolymers (poloxamer; e.g. Pluronic®) and may be present in amounts of about 0.5 wt.% to about 7 wt.%, more preferably about 1 wt.% to about 5 wt.% of the total weight of the composition.
  • surfactants such as polyoxyethylene alcohol ethers (e.g. Brij®), polysorbates (e.g. Tween®) or polyoxypropylene polyoxyethylene copolymers (poloxamer; e.g. Pluronic®) and may be present in amounts of about 0.5 wt.% to about 7 wt.%, more preferably about 1 wt.% to about 5 wt.% of the total weight of the composition.
  • pseudo-emulsifier can be used. Its mechanism of action mainly relies on an enhancement of viscosity. However, pseudo-emulsifiers also possess emulsifying properties.
  • Preferred pseudo-emulsifiers are for example cellulose ethers, gum Arabic or tragacanth. Pseudo-emulsifiers may be present in amounts of about 1 wt.% to about 10 wt.%, more preferably about 3 wt.% to about 7 wt.% of the total weight of the composition.
  • the pharmaceutical composition of the present invention can be formulated in any known manner, preferably as tablets, capsules, granules, pellets or sachets.
  • a particularly preferred pharmaceutical composition is in the form of tablets.
  • the pharmaceutical composition may contain for example dosage amounts of 25, 100 or 150 mg of Erlotinib. Thus the administered amount can be readily varied according to individual tolerance and safety.
  • the pharmaceutical composition of the present invention can be manufactured according to standard methods known in the art.
  • Granulates according to the invention can be obtained by dry compaction or wet granulation. These granulates can subsequently be mixed with e.g. suitable disintegrating agents, glidants and lubricants and the mixture can be compressed into tablets or filled into sachets or capsules of suitable size.
  • Tablets can also be obtained by direct compression of a suitable powder mixture, i.e. without any preceding granulation of the excipients.
  • Suitable powder or granulate mixtures according to the invention are also obtainable by spray drying, lyophilization, melt extrusion, pellet layering, coating of the active pharmaceutical ingredient or any other suitable method.
  • the so obtained powders or granulates can be mixed with one or more suitable ingredients and the resulting mixtures can either be compressed to form tablets or filled into sachets or capsules.
  • the above mentioned methods known in the art also include grinding and sieving techniques permitting the adjustment of desired particle size distributions.
  • Figure 1 shows the XRPD pattern of polymorph A of Erlotinib HCI taken from WO 01/34574 A1.
  • Figure 2 shows the XRPD patterns of a mixture of 90 % polymorph A and 10 % polymorph B of Erlotinib HCI at time 0, after 4 weeks and after 12 weeks (from bottom to top).
  • Figure 3 shows the XRPD patterns of grounded tablets according to the present invention at time 0, after 4 weeks and after 12 weeks (from bottom to top).
  • Figure 4 shows the dissolution profile of a tablet according to the present invention comprising MCC as hydrophilic excipient, compared to the dissolution profiles of tablets comprising 1 wt.% and 3 wt.% sodium lauryl sulfate (SLS), respectively.
  • SLS sodium lauryl sulfate
  • the dissolution of the obtained tablets was measured using the paddle method (USP app. II) in 1000 ml 0.1 N HCI, pH 1 at 37°C and 100 rpm with the addition of 0.5 % sodium lauryl sulfate.
  • the dissolution profile was measured after storage for two and four weeks, respectively, whereby the storage conditions were 40°C/75 % relative humidity and 25°C/60 % relative humidity, respectively.
  • the results of the dissolution tests are summarized in table 3.
  • the dissolution profile of the tablets after storage for four weeks at 40 0 C and 75 % relative humidity is also shown in figure 4.
  • the dissolution profile of the tablets of the present invention is excellent and remains stable during storage even under harsh conditions.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a pharmaceutical composition comprising N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride as active pharmaceutical ingredient and a process for the preparation of such composition.

Description

Pharmaceutical composition comprising N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
Field of the Invention
The present invention relates to a pharmaceutical composition comprising N-(3- ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride as active pharmaceutical ingredient and a process for the preparation of such composition.
Background of the invention
The compound N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine (INN: Erlotinib) is useful in the treatment of hyperproliferative disorders, such as cancers, in mammals. Erlotinib HCI has the following formula (I):
Figure imgf000002_0001
In WO 96/30347, which is incorporated herein by reference in its entirety, the preparation of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinarnine hydrochloride as well as the uses of this compound have been disclosed. In particular, this compound is an inhibitor of tyrosine kinase enzymes, namely as epidermal growth factor receptors and can be used for the treatment and/or prevention of diseases which are associated with tyrosine kinase enzymes such as epidermal growth factor receptors, such as cancer, particularly non small cell lung cancer, colorectal cancer, refractory non small cell lung cancer, pancreatic cancer, ovarian cancer, breast cancer, glioma, head cancer or neck cancer. Recently, two different polymorphs of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4- quinazolinamine hydrochloride, designated as polymorph A and polymorph B, have been disclosed in WO 01/34574, which is incorporated herein by reference. Polymorph B was found to be thermodynamically more stable than polymorph A. This document therefore also discloses a method comprising the step of recrystallisation of a compound comprising both polymorph A and polymorph B into the more stable polymorph B. The more stable polymorph B is further used in the preparation of pharmaceutical compositions.
A further polymorph of the compound N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4- quinazolinamine hydrochloride, namely polymorph E is disclosed in WO 2004/072049. This document further teaches that while polymorph B is thermodynamically more stable than polymorph A, polymorph A exhibits a better solubility and dissolution rate than polymorph B. Polymorph E is said to unexpectedly exhibit the desired increased solubility and dissolution rate with respect to polymorph B and an increased thermodynamic stability compared to polymorph A.
Without disclosing any specific polymorph of N-(3-ethynylphenyl)-6,7-bis(2- methoxyethoxy)-4-quinazolinamine hydrochloride WO 2006/110811 relates to the problem that conventional Erlotinib HCI tablets are only very slightly soluble in water at 37°C. Therefore, the dissolution of conventional Erlotinib HCI tablets is said to be reduced in the fasted state as compared to the fed state. Thus, Erlotinib HCI has limited bioavailability in the fasted state as compared to the fed state, which limits the therapeutic outcome for all treatments requiring Erlotinib HCI. To overcome this problem a nanoparticulate Erlotinib HCI composition comprising particles of the active pharmaceutical ingredient having an effective average particle size of less than 2000 nm and at least one surface stabilizer is suggested. The surface stabilizer is present to stabilize the nanoparticulate form of the composition. A wide range of surface stabilizers is disclosed, including various polymers, low molecular weight oligomers, natural products, and surfactants. The surface stabilizers include non-ionic, ionic anionic, cationic, and zwitterionic compounds or surfactants. Sodium lauryl sulfate is exemplified among a large list of further compounds.
Nanoparticles are difficult to prepare, costly, and difficult to handle when preparing pharmaceutical dosage forms. Therefore, there is a need for further pharmaceutical compositions comprising Erlotinib HCI which overcome the above problems of the prior art, in particular with respect to preparation and handling characteristics, solubility, bioavailability and stability.
It has now surprisingly been found that the above problems can be overcome by providing a pharmaceutical composition comprising polymorph A of N-(3-ethynylphenyl)-6,7-bis(2- methoxyethoxy)-4-quinazolinamine hydrochloride. Thus, the present invention relates to a pharmaceutical composition comprising N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4- quinazolinamine hydrochloride in a thermodynamically stable form.
Description of the invention
Erlotinib HCI can be synthesized using techniques well-known in the art. A synthesis of Erlotinib is disclosed, for example, in WO 96/30347.
Polymorph A of Erlotinib HCI and a method of its preparation is disclosed in WO 01/34574. The X-ray powder diffraction pattern of polymorph A of Erlotinib HCI is shown in attached figure 1. 2-Theta values of characteristic peaks taken from the X-ray powder diffraction pattern of polymorph A of Erlotinib HCI and their relative intensities are summarized in the following table 1.
Table 1 :
Anode: Cu - Wavelength 1 : 1.54056 Wavelength 2: 1.54439 (ReI Intensity: 0.500) Range#1 - Coupled: 3.000 to 40.000 StepSize: 0.040 Step Time: 1.00 Smoothing Width: 0.300 Threshold: 1.0
Figure imgf000004_0001
Thus, polymorph A of Erlotinib HCI is characterized by having characteristic peaks in an X- ray powder diffraction pattern when measured with Cukα radiation expressed in degrees 2- theta at approximately 5.6, 9.8, 18.9 and 23.5.
The term "pharmaceutical composition" refers to single dosage forms, such as tablets, capsules, pellets, etc., as well as powders or granules which are used in the preparation of single dosage forms. Where it is referred to the total weight of the pharmaceutical composition and the pharmaceutical composition is in a single dosage form, the total weight is the weight of the single dosage form excluding, if applicable, the weight of any coating or capsule shell.
It is known form WO 01/34574 and WO 2004/072049 that polymorph A of Erlotinib HCI is thermodynamically unstable. This is confirmed by attached figure 2 which shows the X-ray powder diffraction (XRPD) pattern of a mixture of 90 parts by weight polymorph A and 10 parts by weights polymorph B during storage for 0, 4 and 12 weeks respectively (from bottom to top). From the diffraction patterns it can be seen that the characteristic peaks of polymorph A are decreasing while the characteristic peaks of polymorph B are increasing over time. For example, the relative intensities of the polymorph A peak at a 2-theta angle of 5.6 are decreasing from the bottom to the top while the relative intensities of the polymorph B peak at a 2-theta angle of 6.3 are significantly increasing from the bottom to the top, i.e. during storing for 0, 4 and 12 weeks, respectively. This confirms the prior art knowledge that under conventional conditions polymorph A is thermodynamically unstable and converts into polymorph B.
Contrary to this prior art knowledge, the present invention is based on the surprising finding that polymorph A of Erlotinib HCI can be incorporated into a pharmaceutical composition in a thermodynamically stable form. "Thermodynamically stable" in the sense of the present invention means that in the pharmaceutical composition Erlotinib HCI maintains its polymorphic form A even under harsh storage conditions of 75 % relative humidity and 4O0C for at least 12 weeks, preferably for at least 12 months. Maintaining its polymorphic form A therefore means that polymorph A of Erlotinib HCI during storage is not converted into any other polymorph of Erlotinib HCI, in particular not into polymorph B. The thermodynamic stability of polymorph A of Erlotinib HCI in the pharmaceutical compositon of the present invention is confirmed by attached figure 3 which shows the XRPD patterns of grounded tablets of the present invention at time 0, after 4 weeks and after 12 weeks storage at 75 % relative humidity and 4O0C (from bottom to top). It is evident that the characteristic peaks of polymorph A of Erlotinib HCI do not change in their intensities. Moreover, none of the characteristic peaks of polymorph B of Erlotinib HCI (shown as lines and dots at the bottom of the diagram) occurs in the XRPD patterns of the tablet. This confirms that polymorph A of Erlotinib HCI is thermodynamically stable in the pharmaceutical composition of the present invention and in particular that polymorph A is not converted into polymorph B during storage over at least 12 weeks.
Furthermore, it has surprisingly been found that in one embodiment of the present invention, polymorph A of Erlotinib HCI can be thermodynamically stabilized by the addition of a hydrophilic excipient to the pharmaceutical composition. Further surprising it was found that the addition of a hydrophilic excipient does not only stabilize the polymorphic form of the active pharmaceutical ingredient, but the hydrophilic excipient additionally increases the dissolution of the pharmaceutical composition. Moreover, the increased dissolution is obtained without the requirement of providing the Erlotinib HCI in nanoparticulate form. Thus, the combination of polymorph A of Erlotinib HCI and a hydrophilic excipient in the pharmaceutical composition of the present invention results in several advantages over the prior art formulations. The first advantage is that polymorph A of Erlotinib HCI, which is known to be thermodynamically unstable, is stabilized, a further advantage is that the dissolution of the pharmaceutical composition and thereby the bioavailability of the active pharmaceutical ingredient is increased, and a further advantage is that dissolution and/or bioavailability are increased without the requirement of providing the active pharmaceutical ingredient in nanoparticulate form.
The surprising effect of the hydrophilic excipient on the dissolution profile of the pharmaceutical composition containing polymorph A of Erlotinib HCI is demonstrated by attached figure 4. This figure shows the dissolution profiles of the tablets of example 1 being according to the invention and containing microcrystalline cellulose (MCC) as hydrophilic excipient compared to tablets comprising 1 % and 3 %, respectively, of sodium lauryl sulfate (SLS), a surface stabilizer suggested in WO 2006/110811. It is evident that the hydrophilic excipient in the pharmaceutical composition of the present invention significantly increases the dissolution compared to a surface stabilizer as suggested in the prior art.
Hydrophilic excipients in the sense of the present invention contain molecules that are charge-polarized and capable of hydrogen bonding, enabling them to dissolve more readily in water than in oil or other hydrophobic solvents. A hydrophilic excipient can, for example, be a hydrophilic polymer which contains hydrophilic groups, such as hydroxy groups, amino groups, carboxy groups and/or sulfonate groups. Examples of suitable hydrophilic polymers are polysaccharides, such as microcrystalline cellulose (MCC), hydroxypropylmethyl cellulose (HPMC), carboxymethyl celluloses (CMC) (in particular sodium carboxymethyl cellulose or calcium carboxymethyl cellulose), ethyl cellulose, methyl cellulose, hydroxyethyl cellulose, ethylhydroxyethyl cellulose, and hydroxypropyl cellulose (HPC); polyvinyl pyrrolidone; polyvinyl alcohol; acrylic acid polymers and there salts; polyacryl amides; polymethacrylates; copolymers of vinylpyrrolidone and vinylacetate (such as Kollidon® VA64); polyalkylene glycols, such as polypropylene glycol and polyethylene glycol; block copolymers of polyethylene glycols, such as block copolymers of polyethylene glycol and polypropylene glycol (such as Pluronic®). The hydrophilic polymer can have a weight average molecular weight in the range of about 1000 g/mol to about 150000 g/mol, preferably in the range of about 2000 g/mol to about 90000 g/mol.
Microcrystalline cellulose is a preferred hydrophilic excipient in the pharmaceutical composition of the present invention. The microcrystalline cellulose can have a specific surface area in the range of about 0.78 m2/g to about 1.30 m2/g and/or a mean particle size in the range of about 10 μm to about 100 μm.
Further hydrophilic excipients useful in the pharmaceutical composition of the present invention are, for example, monosaccharides, disaccharides, oligosaccharides and sugar alcohols, such as mannitol, sorbitol, xylitol, isomalt, glucose, fructose or maltose.
The pharmaceutical composition of the present invention can contain one or more hydrophilic excipients. In one embodiment, the hydrophilic excipient is not a surfactant, i.e. it does not contain hydrophilic and hydrophobic parts, such as the hydrophobic fatty acid residue in sodium lauryl sulfate.
In one embodiment of the present invention, the hydrophilic excipient is a hydrophilic polymer, a 2 wt.% solution of which in water exhibits a viscosity in the range of about 0.01 mPa/s to about 8 mPa/s, preferably in the range of about 0.5 mPa/s to about 7 mPa/s, more preferably in the range of about 1 mPa/s to about 6 mPa/s.
The amount of hydrophilic excipient present in the pharmaceutical composition of the present invention is not particularly limited. It can be selected by the person skilled in the art based on the specific requirements of the composition, for example with respect to its compressability. The amount must, however, be sufficient to thermodynamically stabilize polymorphic form A of Erlotinib HCI. For example, the amount can be in the range of about 10 wt.% to about 90 wt.%, preferably in the range of about 10 wt.% to about 75 wt.%, more preferably in the range of about 30 wt.% to about 75 wt.%, most preferred in the range of about 50 wt.% to about 70 wt.%, each based on the total weight of the pharmaceutical composition.
In order to provide a pharmaceutical composition having an optimum dissolution profile, it is preferred that the pharmaceutical composition is essentially free of polymorph B of Erlotinib HCI. Being essentially free of polymorph B means that polymorph B is present in the pharmaceutical composition of the present invention in an amount of less than 5 wt.%, preferably in an amount of less than 1 wt.%, each based on the total amount of Erlotinib HCI. Most preferable, the pharmaceutical composition of the present invention does not contain any polymorph B of Erlotinib HCI. Furthermore, it is preferred that the pharmaceutical composition does not contain any other polymorph of Erlotinib HCI than polymorph A. Thus, the pharmaceutical composition of the present invention preferably comprises Erlotinib HCI essentially only as polymorph A, i.e. at least 95 wt.% of the total amount of Erlotinib HCI in the pharmaceutical composition is present in polymorphic form A, preferably at least 99 wt.%. Most preferred Erlotinib HCI is present in the pharmaceutical composition only in polymorphic form A.
The particle size of the active pharmaceutical ingredient in the pharmaceutical composition of the present invention is not particularly limited. However, in view of the disadvantages associated with the preparation and handling of nanoparticles, it is preferred that the Erlotinib HCI in the pharmaceutical composition of the present invention has a D50 particle size of above 2 μm. D50 particle size means a particle size distribution where 50 vol.% of the total amount of Erlotinib HCI in the pharmaceutical composition has a particle size of above 2 μm when measured with a Master Sizer 2000 using propan-2-ol as dispersant.
It was further found that the advantageous effects of the hydrophilic excipient on the thermodynamic stability of polymorph A of Erlotinib HCI and the dissolution of the pharmaceutical composition are particularly strong when the surface stabilizer is absorbed to or associated with the surface of the Erlotinib HCI particles. This absorption or association can be obtained by intimate mixing polymorph A of Erlotinib HCI and the hydrophilic excipient, for example, by milling, grinding, or triturating.
Therefore, the present invention also relates to a process for the preparation of a pharmaceutical composition as defined above, comprising the step of intimate mixing polymorph A of Erlotinib HCI and a hydrophilic excipient. Preferably the step of intimate mixing is carried out by milling, grinding, or triturating. The process can comprise the further steps of adding additional excipients and forming a solid dosage form, such as by compression, in particular by dry compaction.
The pharmaceutical composition of the present invention can additionally comprise one or more further active pharmaceutical ingredients, in particular one or more compounds useful in treating hyperproliferative disorders, such as cancer or other neoplastic diseases, or the pharmaceutical composition of the present invention can be administered in conjunction with such a compound. Examples of suitable other active pharmaceutical ingredients are disclosed, for example, in WO 2006/110811.
The dosage of Erlotinib HCI can vary within wide limits depending on the disease to be controlled, the age and the individual condition of the patient and the mode of administration, and will, of course, be fit to the individual requirements in each particular case. For adult patients a daily dosage of about 1 mg to about 1000 mg, especially about 5 mg to about 500 mg, preferably about 25 mg to about 200 mg is applicable. Depending on severity of the disease and the precise pharmacokinetic profile, the compound can be administered with one or several daily dosage units, e.g. in one to three dosage units. The pharmaceutical composition of the present invention may further comprise one or more pharmaceutically acceptable excipients, such as fillers, binding agents, lubricants, flow enhancers, antisticking agents, disintegrating agents and solubilizers. As pharmaceutically acceptable excipients conventional excipients known to the person skilled in the art may be used. See for example "Lexikon der Hilfsstoffe fϋr Pharmazie, Kosmetik und angrenzende Gebiete", edited by H. P. Fiedler, 4th Edition, Edito Cantor, Aulendorf and earlier editions, and "Handbook of Pharmaceutical Excipients", Third Edition, edited by Arthur H. Kibbe, American Pharmaceutical Association, Washington, USA, and Pharmaceutical Press, London.
Preferred examples of the fillers are lactose, mannitol, sorbitol or microcrystalline cellulose. The filler is suitably present in an amount of about 0 wt.% to about 30 wt.% of the total weight of the composition.
The binding agent can for example be microcrystalline cellulose (MCC) or hydroxypropylmethyl cellulose (HPMC). Preferably, the binding agent is present in an amount of about 1 wt.% to about 25 wt.%, more preferably at about 2 wt.% to about 10 wt.% of the total weight of the composition.
The lubricant is preferably a stearate such as earth alkali metal stearate, such as magnesium stearate or sodium stearyl fumarate. The lubricant is suitably present in an amount of about 0.5 wt.% to about 2.5 wt.% of the total weight of the composition.
Suitable disintegrating agents are for example cellulose derivatives such croscarmellose sodium, starch derivatives such as sodium carboxymethyl starch, pregelatinized starch, synthetic polymers such as cross-linked polyvinylpyrrolidone (crospovidone) or sodium bicarbonate. The disintegrant or disintegrant mixture is suitably present in an amount of about 1 wt.% to about 20 wt.%, more preferably at about 5 wt.% to about 10 wt.% of the total weight of the composition.
The flow enhancer can for example be colloidal silicon dioxide. Preferably, the flow enhancer is present in an amount of about 0.5 wt.% to about 8 wt.%, more preferably at about 1 wt.% to about 4 wt.% of the total weight of the composition. The antisticking agent is for example talcum and may be present in amounts of about 1 wt.% to about 5 wt.%, more preferably in an amount of about 1.5 wt.% to about 3 wt.% of the total weight of the composition.
An improvement of the solubility of the active pharmaceutical ingredient can for example be achieved by the addition of complex forming agents/compounds (e.g. sodium benzoate, sodium salicylate or cyclodextrins), the alternation of solvent properties (e.g. by adding PVP or polyethylene glycols) or the addition of solubilizers which form tenside micelles (e.g. surfactants).
Suitable solubilizers are for example surfactants such as polyoxyethylene alcohol ethers (e.g. Brij®), polysorbates (e.g. Tween®) or polyoxypropylene polyoxyethylene copolymers (poloxamer; e.g. Pluronic®) and may be present in amounts of about 0.5 wt.% to about 7 wt.%, more preferably about 1 wt.% to about 5 wt.% of the total weight of the composition.
Alternatively, a pseudo-emulsifier can be used. Its mechanism of action mainly relies on an enhancement of viscosity. However, pseudo-emulsifiers also possess emulsifying properties.
Preferred pseudo-emulsifiers are for example cellulose ethers, gum Arabic or tragacanth. Pseudo-emulsifiers may be present in amounts of about 1 wt.% to about 10 wt.%, more preferably about 3 wt.% to about 7 wt.% of the total weight of the composition.
A person skilled in the art may use these or other excipients depending on the selected process of preparing the pharmaceutical composition of the invention.
The pharmaceutical composition of the present invention can be formulated in any known manner, preferably as tablets, capsules, granules, pellets or sachets. A particularly preferred pharmaceutical composition is in the form of tablets. The pharmaceutical composition may contain for example dosage amounts of 25, 100 or 150 mg of Erlotinib. Thus the administered amount can be readily varied according to individual tolerance and safety.
The pharmaceutical composition of the present invention can be manufactured according to standard methods known in the art. Granulates according to the invention can be obtained by dry compaction or wet granulation. These granulates can subsequently be mixed with e.g. suitable disintegrating agents, glidants and lubricants and the mixture can be compressed into tablets or filled into sachets or capsules of suitable size.
Tablets can also be obtained by direct compression of a suitable powder mixture, i.e. without any preceding granulation of the excipients.
Suitable powder or granulate mixtures according to the invention are also obtainable by spray drying, lyophilization, melt extrusion, pellet layering, coating of the active pharmaceutical ingredient or any other suitable method. The so obtained powders or granulates can be mixed with one or more suitable ingredients and the resulting mixtures can either be compressed to form tablets or filled into sachets or capsules. The above mentioned methods known in the art also include grinding and sieving techniques permitting the adjustment of desired particle size distributions.
Figures
Figure 1 shows the XRPD pattern of polymorph A of Erlotinib HCI taken from WO 01/34574 A1.
Figure 2 shows the XRPD patterns of a mixture of 90 % polymorph A and 10 % polymorph B of Erlotinib HCI at time 0, after 4 weeks and after 12 weeks (from bottom to top).
Figure 3 shows the XRPD patterns of grounded tablets according to the present invention at time 0, after 4 weeks and after 12 weeks (from bottom to top).
Figure 4 shows the dissolution profile of a tablet according to the present invention comprising MCC as hydrophilic excipient, compared to the dissolution profiles of tablets comprising 1 wt.% and 3 wt.% sodium lauryl sulfate (SLS), respectively.
The following example further illustrates the invention but is not to be construed as limiting. Example
Tablets where prepared with the ingredients according to table 2
Table 2
Figure imgf000013_0001
Avicel PH 101 , Erlotinib HCI Polymorph A, sodium lauryl sulfate and Kollidon CL where mixed and triturated before sieving through a 125 μm sieve. The mixture was pressed, crushed and sieved over a 630 μm sieve. The remaining excipients were added, the mixture was again mixed and pressed into tablets.
The dissolution of the obtained tablets was measured using the paddle method (USP app. II) in 1000 ml 0.1 N HCI, pH 1 at 37°C and 100 rpm with the addition of 0.5 % sodium lauryl sulfate. The dissolution profile was measured after storage for two and four weeks, respectively, whereby the storage conditions were 40°C/75 % relative humidity and 25°C/60 % relative humidity, respectively. The results of the dissolution tests are summarized in table 3.
Table 3
Figure imgf000013_0002
The dissolution profile of the tablets after storage for four weeks at 400C and 75 % relative humidity is also shown in figure 4. The dissolution profile of the tablets of the present invention is excellent and remains stable during storage even under harsh conditions.

Claims

Claims
1. Pharmaceutical composition comprising polymorph A of N-(3-ethynylphenyl)-6,7- bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride in a thermodynamically stable form.
2. Pharmaceutical composition according to claim 1 , further comprising a hydrophilic excipient.
3. Pharmaceutical composition according to claim 2, wherein the hydrophilic excipient is selected from the group consisting of hydrophilic polymers, monosaccharides, disaccharides, oligosaccharides and sugar alcohols.
4. Pharmaceutical composition according to claim 3, wherein the hydrophilic excipient is selected from the group consisting of polysaccharides, such as microcrystalline cellulose, hydroxypropylmethyl cellulose, carboxymethyl celluloses, ethyl cellulose, methyl cellulose, hydroxyethyl cellulose, ethylhydroxyethyl cellulose, and hydroxypropyl cellulose; polyvinyl pyrrolidone; polyvinyl alcohol; acrylic acid polymers and there salts; polyacryl amides; polymethacrylates; copolymers of vinylpyrrolidone and vinylacetate; polyalkylene glycols, such as polypropylene glycol and polyethylene glycol; block copolymers of polyethylene glycols, such as block copolymers of polyethylene glycol and polypropylene glycol; mannitol; sorbitol; xylitol; isomalt; glucose; fructose; maltose; and mixtures thereof.
5. Pharmaceutical composition according to claim 4, wherein the hydrophilic excipient is microcrystalline cellulose having a specific surface area in the range of about 0.78 m2/g to about 1.30 m2/g and/or a mean particle size in the range of about 10 μm to about 100 μm.
6. Pharmaceutical composition according to any of the preceding claims, being essentially free of polymorph B of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4- quinazolinamine hydrochloride.
7. Pharmaceutical composition according to any of the preceding claims, wherein the N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride has a D50 particle size of above 2 μm.
8. Pharmaceutical composition according to any of the preceding claims, wherein the surface stabilizer is absorbed to or associated with the surface of N-(3- ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride particles.
9. Pharmaceutical composition according to any of the preceding claims, being in the form of a solid dosage form, such as tablets, capsules, granules, pellets and sachets.
10. Pharmaceutical composition according to any of the preceding claims, obtainable by a process comprising the step of intimate mixing polymorph A of N-(3- ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride and a hydrophilic excipient.
11. Pharmaceutical composition according to claim 10, wherein the step of intimate mixing is carried out by milling, grinding, or triturating.
12. Process for the preparation of a pharmaceutical composition as defined in any of claims 1-11 , comprising the step of intimate mixing polymorph A of N-(3- ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride and a hydrophilic excipient.
13. Process according to claim 12, wherein the step of intimate mixing is carried out by milling, grinding, or triturating.
14. Process according to claim 12 or 13, comprising the further steps of adding additional excipients and forming a solid dosage form, such as by compression, in particular by dry compaction.
15. Use of a hydrophilic excipient for stabilizing the polymorphic form of polymorph A of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride.
PCT/EP2010/051174 2009-02-02 2010-02-01 Pharmaceutical composition comprising n-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride Ceased WO2010086441A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09001406A EP2213281A1 (en) 2009-02-02 2009-02-02 Pharmaceutical composition comprising N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
EP09001406.9 2009-02-02

Publications (1)

Publication Number Publication Date
WO2010086441A1 true WO2010086441A1 (en) 2010-08-05

Family

ID=40651336

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/051174 Ceased WO2010086441A1 (en) 2009-02-02 2010-02-01 Pharmaceutical composition comprising n-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride

Country Status (2)

Country Link
EP (1) EP2213281A1 (en)
WO (1) WO2010086441A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014118112A1 (en) 2013-01-29 2014-08-07 Synthon B.V. Pharmaceutical composition comprising erlotinib hydrochloride
CN105168172A (en) * 2015-08-26 2015-12-23 浙江华义医药有限公司 Erlotinib hydrochloride tablet with improved dissolution rate and stability and preparation method thereof
WO2016082879A1 (en) * 2014-11-27 2016-06-02 Synthon B.V. Pharmaceutical composition comprising erlotinib hydrochloride
JP2020075923A (en) * 2018-11-09 2020-05-21 日本化薬株式会社 Pharmaceutical tablets comprising erlotinib as an effective ingredient
JP2020090484A (en) * 2018-11-27 2020-06-11 日本化薬株式会社 Medicine tablet comprising erlotinib as active principle
JP2020090456A (en) * 2018-12-05 2020-06-11 日本化薬株式会社 Pharmaceutical tablets containing erlotinib as active ingredient

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030347A1 (en) 1995-03-30 1996-10-03 Pfizer Inc. Quinazoline derivatives
WO2001034574A1 (en) 1999-11-11 2001-05-17 Osi Pharmaceuticals, Inc. Stable polymorph of n-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof
WO2004072049A1 (en) 2003-02-17 2004-08-26 F. Hoffmann-La Roche Ag Polymorph of {6,7-bis(2-methoxy-ethoxy)-quinazolin-4-yl}-(3e)
WO2006110811A1 (en) 2005-04-12 2006-10-19 Elan Pharma International Limited Nanoparticulate quinazoline derivative formulations
WO2008102369A1 (en) * 2007-02-21 2008-08-28 Natco Pharma Limited Novel polymorphs of erlotinib hydrochloride and method of preparation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030347A1 (en) 1995-03-30 1996-10-03 Pfizer Inc. Quinazoline derivatives
WO2001034574A1 (en) 1999-11-11 2001-05-17 Osi Pharmaceuticals, Inc. Stable polymorph of n-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof
WO2004072049A1 (en) 2003-02-17 2004-08-26 F. Hoffmann-La Roche Ag Polymorph of {6,7-bis(2-methoxy-ethoxy)-quinazolin-4-yl}-(3e)
WO2006110811A1 (en) 2005-04-12 2006-10-19 Elan Pharma International Limited Nanoparticulate quinazoline derivative formulations
WO2008102369A1 (en) * 2007-02-21 2008-08-28 Natco Pharma Limited Novel polymorphs of erlotinib hydrochloride and method of preparation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Handbook of Pharmaceutical Excipients", AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, USA
"Lexikon der Hilfsstoffe fur Pharmazie, Kosmetik und angrenzende Gebiete", EDITO CANTOR, AULENDORF AND EARLIER EDITIONS
NORRIS T ET AL: "Discovery of a new stable polymorph of 4-(3-ethynylphenylamino)-6,7-b is(2-methoxyethoxy)quinazolinium methanesulfonate using near-infrared spectroscopy to monitor form change kinetics", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 2, CHEMICAL SOCIETY. LETCHWORTH, GB, vol. 2, 1 January 2000 (2000-01-01), pages 2498 - 2502, XP002261707, ISSN: 1472-779X *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014118112A1 (en) 2013-01-29 2014-08-07 Synthon B.V. Pharmaceutical composition comprising erlotinib hydrochloride
WO2016082879A1 (en) * 2014-11-27 2016-06-02 Synthon B.V. Pharmaceutical composition comprising erlotinib hydrochloride
CN105168172A (en) * 2015-08-26 2015-12-23 浙江华义医药有限公司 Erlotinib hydrochloride tablet with improved dissolution rate and stability and preparation method thereof
JP2020075923A (en) * 2018-11-09 2020-05-21 日本化薬株式会社 Pharmaceutical tablets comprising erlotinib as an effective ingredient
JP7370124B2 (en) 2018-11-09 2023-10-27 日本化薬株式会社 Pharmaceutical tablets containing erlotinib as the active ingredient
JP2020090484A (en) * 2018-11-27 2020-06-11 日本化薬株式会社 Medicine tablet comprising erlotinib as active principle
JP7370126B2 (en) 2018-11-27 2023-10-27 日本化薬株式会社 Pharmaceutical tablets containing erlotinib as the active ingredient
JP2020090456A (en) * 2018-12-05 2020-06-11 日本化薬株式会社 Pharmaceutical tablets containing erlotinib as active ingredient

Also Published As

Publication number Publication date
EP2213281A1 (en) 2010-08-04

Similar Documents

Publication Publication Date Title
JP6895779B2 (en) Azilsartan-containing solid pharmaceutical composition
EP2213281A1 (en) Pharmaceutical composition comprising N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
EP2359813A1 (en) Pharmaceutical composition comprising N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamid
EP3620156A1 (en) Composition having improved water solubility and bioavailability
EP2902016A1 (en) Febuxostat tablet
US20240293323A1 (en) Pharmaceutical compositions of an epidermal growth factor receptor inhibitor
EP2291079B1 (en) Formulations for cathepsin k inhibitors
CN112384223B (en) Pharmaceutical composition containing poorly soluble alkaline agent
PL192545B1 (en) Novel compositions of eprosartan
JP2022532540A (en) Pharmaceutical composition containing axitinib
EP4436554A1 (en) Pharmaceutical compositions comprising eltrombopag
EP2158912A1 (en) Pharmaceutical composition comprising N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
WO2014118112A1 (en) Pharmaceutical composition comprising erlotinib hydrochloride
US20240415777A1 (en) Instant release pharmaceutical preparation of anticoagulant and preparation method therefor
WO2021220295A1 (en) Immediate release pharmaceutical compositions comprising palbociclib
EP2644197A1 (en) Novel Pharmaceutical Compositions of Entecavir
US20100003319A1 (en) Raloxifene immediate release tablets
KR101068475B1 (en) Sustained release formulation comprising cilostazol and preparation method thereof
WO2007049292A1 (en) Pharmaceutical formulation of losartan
WO2023195954A1 (en) A film coated tablet comprising a solid dispersion of selexi̇pag
EP2644196B1 (en) Pharmaceutical compositions of Entecavir
KR101944085B1 (en) Solid oral dosage form containing valsartan, and preparation method therefor
EP3843702B1 (en) Immediate release fixed-dose combination of memantine and donepezil
AU2020100442A4 (en) Dosage form providing prolonged release of tapentadol phosphoric acid salt
EP4382097A1 (en) A tablet comprising teriflunomide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10701555

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10701555

Country of ref document: EP

Kind code of ref document: A1